Literature DB >> 11193896

Metabolism of CPT-11. Impact on activity.

L P Rivory1.   

Abstract

Irinotecan (CPT-11) is a semi-synthetic camptothecin with a broad spectrum of clinical activity. It is a prodrug that is cleaved by esterases to the potent topoisomerase I poison, SN-38. In humans, this activation is relatively inefficient, but this may result in a more protracted formation of SN-38 lactone. Some intratumoral activation may also occur, but the significance of this process is uncertain. CPT-11 is metabolized by cytochrome P450 3A to yield a number of comparatively inactive compounds. SN-38 is glucurono-conjugated in the liver, and this metabolite, although inactive, may participate in the enterohepatic cycling of SN-38 after hydrolysis in the intestinal lumen. Overall, the production of SN-38 from CPT-11 is the result of the complex interplay of several metabolic pathways and the source of considerable interpatient variability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193896     DOI: 10.1111/j.1749-6632.2000.tb07039.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

Authors:  Qingyu Zhou; Alex Sparreboom; Eng-Huat Tan; Yin-Bun Cheung; Ann Lee; Donald Poon; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 2.  Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.

Authors:  Wolf-Dieter Janthur; Nathan Cantoni; Christoph Mamot
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

3.  Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

Authors:  C Alliot; M Barrios
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

Review 4.  Onivyde for the therapy of multiple solid tumors.

Authors:  Haijun Zhang
Journal:  Onco Targets Ther       Date:  2016-05-20       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.